Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Invested Capital (2016 - 2026)

Lexaria Bioscience's Invested Capital history spans 12 years, with the latest figure at $6.2 million for Q1 2026.

  • Quarterly results put Invested Capital at $6.2 million for Q1 2026, down 8.14% from a year ago — trailing twelve months through Feb 2026 was $6.2 million (down 8.14% YoY), and the annual figure for FY2025 was $2.6 million, down 66.02%.
  • Invested Capital for Q1 2026 was $6.2 million at Lexaria Bioscience, up from $4.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $11.2 million in Q1 2022 to a low of $2.6 million in Q3 2025.
  • The 5-year median for Invested Capital is $6.1 million (2024), against an average of $6.3 million.
  • The sharpest move saw Invested Capital soared 185.78% in 2024, then plummeted 66.02% in 2025.
  • Year by year, Invested Capital stood at $5.9 million in 2022, then crashed by 43.14% to $3.4 million in 2023, then skyrocketed by 178.53% to $9.4 million in 2024, then tumbled by 51.85% to $4.5 million in 2025, then skyrocketed by 37.29% to $6.2 million in 2026.
  • According to Business Quant data, Invested Capital over the past three periods came in at $6.2 million, $4.5 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.